Broedl Uli C, Jin Weijun, Fuki Ilia V, Millar John S, Rader Daniel J
Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
J Lipid Res. 2006 Oct;47(10):2191-7. doi: 10.1194/jlr.M600036-JLR200. Epub 2006 Jul 30.
Endothelial lipase (EL) plays an important physiological role in modulating HDL metabolism. Data suggest that plasma contains an inhibitor of EL, and previous studies have suggested that apolipoprotein A-II (apoA-II) inhibits the activity of several enzymes involved in HDL metabolism. Therefore, we hypothesized that apoA-II may reduce the ability of EL to influence HDL metabolism. To test this hypothesis, we determined the effect of EL expression on plasma phospholipase activity and HDL metabolism in human apoA-I and human apoA-I/A-II transgenic mice. Expression of EL in vivo resulted in lower plasma phospholipase activity and significantly less reduction of HDL-cholesterol, phospholipid, and apoA-I levels in apoA-I/A-II double transgenic mice compared with apoA-I single transgenic mice. We conclude that the presence of apoA-II on HDL particles inhibits the ability of EL to influence the metabolism of HDL in vivo.
内皮脂肪酶(EL)在调节高密度脂蛋白(HDL)代谢中发挥着重要的生理作用。数据表明血浆中含有EL的抑制剂,并且先前的研究表明载脂蛋白A-II(apoA-II)可抑制参与HDL代谢的几种酶的活性。因此,我们推测apoA-II可能会降低EL影响HDL代谢的能力。为了验证这一假设,我们在人apoA-I和人apoA-I/A-II转基因小鼠中确定了EL表达对血浆磷脂酶活性和HDL代谢的影响。与apoA-I单转基因小鼠相比,EL在体内的表达导致apoA-I/A-II双转基因小鼠的血浆磷脂酶活性降低,并且HDL胆固醇、磷脂和apoA-I水平的降低明显较少。我们得出结论,HDL颗粒上apoA-II的存在会抑制EL在体内影响HDL代谢的能力。